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Abstract 23 
Background: Hyperfiltration (HF) occurs early in diabetes or obesity (OB)-associated renal disease. 24 
Alterations of glomerular filtration rate (GFR) in childhood OB remain unclear. 25 
Objectives: To compare the prevalence of GFR alterations and its association with uric acid in 26 
children and adolescents with type 1 diabetes (T1D) vs overweight (OW)/OB. 27 
Methods: Cross-sectional study of 29 youths (aged: 13 ± 2 years) with T1D (disease duration: 7 ± 3 28 
years) and 165 with OW/OB (aged: 11 ± 3 years). Patients with an albumin-creatinine ratio >3.39 29 
mg/mmol were excluded. GFR was estimated with creatinine-cystatin C Zappitelli equation. HF and 30 
low GFR were defined by a GFR > 135 and <90 mL/min.1.73 m2, respectively. 31 
Results: HF was higher in children with T1D vs OW/OB (28% vs 10%, P < .005). Children with 32 
OW/OB also showed a 10% of low GFR. In patients with T1D, HbA1c (β = .8, P < .001), and systolic 33 
blood pressure (β = 11.4, P < .005) were independent predictors of GFR (R2 = .65). In OW/OB, HF 34 
cases were almost limited to prepubertal children and low GFR to pubertal ones. GFR in OW/OB 35 
was associated with age (β = −2.2, P < .001), male sex (β = −11.6, P < .001), and uric acid (β = −.05, 36 
P < .001) in adjusted models (R2 = .33). 37 
Conclusions: GFR alterations were different between youths with T1D and with OW/OB. Higher 38 
uric acid, older age, and puberty were related to lower GFR values in OW/OB children. Longitudinal 39 
studies will determine if low GFR is consequence of a rapid GFR decline in pediatric patients with 40 
OW/OB. 41 
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 1 Introduction 44 
 Obesity (OB) and diabetes are the leading risk factors for chronic kidney disease (CKD) that have 45 
been pushing upward its prevalence in the last years.1 CKD is an important contributor to disability, 46 
morbidity, and mortality and constitutes one of the non-communicable causes of death that increased 47 
the most in the past 20 years.2 Thus, the need for markers of early renal dysfunction is at the 48 
spotlight.3 In the development of CKD in children and adolescents with type 1 diabetes (T1D) and 49 
those without diabetes but with overweight (OW)/OB, an early stage of renal hyperfiltration (HF) is 50 
proposed. In children and adolescents with T1D, HF has been associated with increased risk of 51 
microalbuminuria and of a rapid decline in glomerular filtration rate (GFR),4,5 a predominant clinical 52 
feature of diabetic nephropathy.6 Nonetheless, a recent report from the DCCT/EDIC has 53 
underestimated the role of HF as a risk factor for CKD or macroalbuminuria in 446 adults with T1D 54 
followed during a median of 28 years.7 Therefore, if HF has clinical relevance in children and 55 
adolescents with T1D remains yet to be determined. Unlike HF, increasing uric acid levels were 56 
associated with worse renal outcomes, cardiovascular events and mortality in adults with T1D.8,9 57 
However, adolescents with T1D showed reduced uric acid levels, underscoring its use as a risk factor 58 
in these patients.10,11 Even though, increasing uric acid levels in pediatric T1D may still be 59 
associated with a rapid GFR decline, as an inverse correlation with GFR was shown.10,11 On the 60 
other hand, a study showed that children and adolescents with OW/OB without diabetes featured HF 61 
at a similar proportion than those with T1D.12 However, no other studies compared both pediatric 62 
populations. The comparison of GFR values between children with OW/OB vs normal-weight peers 63 
showed inconsistent results; thus, the impact of childhood OW/OB on renal function remains 64 
unclear.12-16 While some authors reported associations between decreased GFR and increasing body 65 
mass index (BMI) and presence of cardiometabolic risk factors, others did the same with elevated 66 
GFR.12-16 In an Italian retrospective study including 2957 children (aged: 3-18 years) with OB, z-67 
BMI positively correlated with GFR. However, pubertal development, HOMA-IR, and duration of 68 
OB were all inversely correlated with GFR and the study concluded that longer duration of OB in 69 
children could impact negatively the GFR.14 If similar alterations of the GFR are present or not in 70 
children and adolescents with T1D and with OW/OB without diabetes is relevant for establishing 71 
prevention strategies. In regard to uric acid levels, an association with cardiometabolic risk factors in 72 
children and adolescents with OW/OB was clearly established.15,17,18 However, its association with 73 
GFR alterations has not been analyzed in this age group. The TODAY study showed that higher uric 74 
acid levels were associated with increased risk of hypertension and microalbuminuria in youth with 75 
type 2 diabetes (T2D).19 Thus, uric acid constitutes a candidate biomarker for screening youths with 76 
OB showing elevated risk of renal impairment. The importance of identifying such patients arises 77 
from the prolonged exposure to other comorbid CKD risk factors, apart from OB, like insulin 78 
resistance and dyslipidemia. This fact might contribute to explain why at similar ages children and 79 
adolescents with T2D presented a 2.5x higher risk of diabetic kidney disease and a 4x higher risk of 80 
renal failure than those with T1D.20,21 Our hypothesis was that GFR alterations and its associations 81 
with uric acid levels in children with OW/OB would be similar to those observed in children with 82 
T1D. The aim of this study was to evaluate and to compare the prevalence of GFR alterations, and to 83 
analyze its association with uric acid in children and adolescents with T1D vs OW/OB. Secondary 84 
analysis included the effects of cardiometabolic risk factors over serum uric acid in OW/OB. 85 
2 | METHODS 86 
2.1 | Study design and sample size 87 
This was a prospective, single-center, cross-sectional study. The expected prevalence of renal HF in 88 
the group of patients with OW/OB was 15% according to the literature.12 The sample size to detect 89 
such prevalence with a 5% of accuracy and a 95% confidence was 196. In order to calculate the 90 
number of patients with T1D in the study, an expected HF prevalence of 30% was set.4,12 Next, we 91 
used a non-inferiority approach for the comparison of two proportions with a critical value (α) = .05, 92 
an 80% power and a non-inferiority margin (δ) of −0.10. The resulting number of patients with T1D 93 
to be included was 24. OpenEpi (Emory University, Atlanta, Georgia) and R (R Foundation, Vienna, 94 
Austria) were used for sample size calculations. 95 
2.2 | Study population 96 
Children and adolescents (aged: 5-17 years) with OW/OB and without diabetes who were referred 97 
for nutritional counseling to the Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico 98 
Churruca-Visca, Buenos Aires, Argentina during April 2017 to April 2019 were invited to participate 99 
(n = 196). Exclusion criteria were: (a) any congenital, concomitant, or incident endocrine disease (n 100 
= 5); (b) congenital hepatic or renal diseases (n = 1); (c) asthma or autoimmune diseases (n = 6); (d) 101 
clinical signs of any infectious disease or a high sensitivity C-reactive protein (hsCRP) > 10 mg/L (n 102 
= 14); (e) urinary albumin-creatinine ratio (ACR) > 3.39 mg/mmol in a first-morning void (n = 3); 103 
and (f) use of psychiatric medication (n = 2). The final number of children and adolescents with 104 
OW/OB studied was 165. Although this number was lower than estimated through sample size 105 
calculations, the observed power for the comparison of GFR alterations was 70%. T1D was diagnosed 106 
according to ISPAD guidelines.22 Every child and adolescent with T1D (aged: 5-17 years) followed 107 
up in our center was invited to participate in the study. Out of 40 patients with T1D, 36 agreed to 108 
participate. Exclusion criteria were ACR >3.39 mg/mmol (n = 2), fasting c-peptide levels >0.2 109 
mmol/L (n = 1), concomitant liver disease and use of any other medication different from insulin. 110 
One patient was excluded as it was born prematurely with an extremely low birth weight (900 g), as 111 
well as, three other patients who missed the protocol examinations. The final number of children and 112 
adolescents with T1D was 29. All the patients studied in the protocol and their legal tutors or parents 113 
gave their written consent and assent to participate in the study. The Bioethics Committee of the 114 
Complejo Médico Churruca- Visca reviewed and approved the study protocol. All the procedures 115 
within the study followed the Ethical Principles stated in the Declaration of Helsinki. 116 
2.3 | Clinical and biochemical assessment 117 
Every patient did a clinical examination including weight, height, waist circumference, and blood 118 
pressure (BP). BMI was calculated and OW/OB classified according to the definitions of the World 119 
Health Organization (WHO).23 WC was measured at the midpoint between the iliac crest and the 120 
last rib and elevated WC classified as >90th percentile according to the Bogalusa Heart Study.24 BP 121 
was recorded as the average of two measurements made after the patient was rested in the sitting 122 
position for 5 minutes. Guidelines of the American Association of Pediatrics were used to define 123 
elevated BP.25 Pubertal development was assessed by Tanner criteria. Puberty was defined by a 124 
Tanner stage >I in children aged >10 years or less if signs of pubertal development were present. All 125 
the patients collected a first-morning void and blood samples were drawn after 12 hours overnight 126 
fast. To avoid the interference of physical exercise in ACR values, subjects were asked not to perform 127 
any physical activity 2 days before the urine sample collection. Creatinine (IDMS-traceable Jaffé, 128 
Beckman Coulter) and cystatin C (immunoturbidimetry, Diazyme, Poway, California) were 129 
measured in a DxC 800 autoanalyzer (Beckman Coulter). The GFR was calculated by the combined 130 
creatinine and cystatin C Zappitelli equation.26 Nonesterified fatty acids (NEFA) levels were 131 
measured by a spectrophotometric method (Randox, Kearneysville West Virginia). Glucose, uric 132 
acid, insulin, lipids, hsCRP, and ACR were measured by standardized methods (Beckman Coulter). 133 
HF was defined as GFR > 135 mL/ min.1.73 m2 and low GFR as <90 mL/min.1.73 m2. The reference 134 
interval of GFR used (90-135 mL/min.1.73 m2) was accepted by a verification process in 26 samples 135 
from normal weight children and adolescents according to the EP28-A3c CLSI protocol. 136 
2.4 | Statistical analysis 137 
The Shapiro–Wilk test was used to evaluate the normal distribution of continuous variables. 138 
Comparisons were made by the Student t test or Mann-Whitney U test, according to data distribution. 139 
For the comparison of categorical variables, chi-square test was used. When comparing more than 140 
three categories, Benjamini-Hochberg correction for multiple comparisons was applied. Two-way 141 
analysis of variance (ANOVA) was used to evaluate differences between male and female patients 142 
with or without GFR alterations across the children with OW/OB. Variables with a skewed 143 
distribution were log-transformed before entering the analysis. Univariate correlations were assessed 144 
by Spearman Correlation test. Stepwise multiple linear regression was used to look for independent 145 
predictors of GFR and uric acid levels. Standardized residuals from linear regression tests were 146 
checked for normality to be confident of the model adequacy. SPSS 25.0 (IBM) was used for 147 
statistical analyses. Statistically significant tests showed a significance value (P) < .05. 148 
3 | RESULTS 149 
3.1 | General characteristics of the studied population 150 
The 29 patients with T1D were exclusively under treatment with insulin. Continuous subcutaneous 151 
insulin infusion was the treatment modality in seven patients, while the rest were using multiple daily 152 
injections. Regarding the metabolic control, 3 patients had an HbA1c <53 mmol/mol and 12 of them 153 
<69 mmol/mol. The median disease duration was 7 years, (Q1-Q3) (5-10) years. Out of the 29 154 
patients, eight showed positive autoantibodies for other diseases (one celiac disease and seven thyroid 155 
antibodies). None of them presented any microvascular or macrovascular complication. Table 1 156 
shows the general characteristics of the children and adolescents with T1D and with OW/OB. The 157 
group of patients with T1D was older and predominantly pubertal in comparison with the patients 158 
with OW/OB. As expected, both groups differed in the z-BMI, waist circumference, glucose 159 
metabolism markers, and NEFA levels. Regarding lipid levels, T1D patients showed higher HDL-C 160 
levels (Table 1). In addition, patients with T1D exhibited lower cystatin C and uric acid, as well as 161 
higher GFR and ACR than OW/OB. Creatinine concentration was similar between patients with T1D 162 
and OW/OB. A significant interaction on GFR values was observed between the groups and pubertal 163 
stage (F = 6.610; P = .011). The difference in GFR was larger among pubertal patients of the different 164 
groups (125 ± 23 vs 104 ± 17 mL/min.1.73 m2, for T1D and OW/OB groups, respectively). The 165 
prevalence of elevated BP and the concentration of hsCRP was similar between the groups. 166 
3.2 | Alterations of the GFR in the studied population The prevalence of HF in children and 167 
adolescents with T1D was significantly higher than in those with OW/OB (Figure 1). In the OW/OB 168 
group, a 10% of the subjects showed low GFR (Figure 1). Pooled together, the alterations of the GFR 169 
were similarly prevalent among T1D and OW/OB patients (28% vs 20%, P = .220, respectively). 170 
3.3 | Correlation of GFR with uric acid levels and cardiometabolic risk factors in T1D 171 
In patients with T1D, GFR correlated with HbA1c (r = .58, P = .001); z-SBP (r = .59, P = .001); and 172 
triglycerides (r = .38, P = .041). Uric acid levels and other cardiometabolic risk factors were not 173 
significantly correlated with GFR (P > .05). In a sex- and age-adjusted model HbA1c (β(95% CI) = 174 
0.8 (0.4-1.1), P < .001) and z-SBP (β = 11.4 (4.0-18.8), P = .005) were independent predictors of 175 
GFR describing more than half of its variability (R2 = .65). 176 
3.4 | Correlation of GFR with uric acid levels and cardiometabolic risk factors in OW/OB 177 
In children and adolescents with OW/OB, the GFR alterations differed according to pubertal stage. 178 
Almost every patient, except one with HF, was prepubertal and almost all the patients with low GFR, 179 
except one, were pubertal (see Supplementary Material for description of these two cases). For further 180 
analyses, these two patients were excluded and comparisons were made on prepubertal children (n = 181 
94) by separate from pubertal ones (n = 69). Clinical and biochemical characteristics of these patients 182 
divided by pubertal development according to sex and the presence of GFR alterations are in Tables 183 
S1 and S2. Prepubertal children with HF showed an improved cardiometabolic risk profile 184 
characterized by lower WC, uric acid and NEFA levels than those with GFR values between 90 and 185 
135 mL/ min.1.73 m2 (Table S1). Differences between female and male prepubertal children were 186 
evident in cystatin C and ACR but not in creatinine or uric acid levels (Table S1). Among the pubertal 187 
patients, those with low GFR were preferentially male and showed higher LDL-C, non-HDL-C and 188 
uric acid than those with GFR between 90 and 135 mL/min.1.73 m2. Sex differences were observed 189 
in HDL-C, cystatin C, and GFR (Table S2). Table S3 shows the univariate correlations of GFR with 190 
metabolic variables in prepubertal and pubertal children by separate. The only variables that 191 
differently correlated with GFR according to the pubertal stage were ACR, NEFA, and plasma lipids. 192 
In prepubertal children, GFR directly correlated with ACR and inversely with NEFA levels (Table 193 
S3). In pubertal subjects, HDL-C positively correlated with GFR, while LDL-C did it inversely (Table 194 
S3). A trend toward a lower GFR was evident as age, pubertal development, WC, LDL-C, uric acid, 195 
NEFA, and other cardiometabolic risk factors increased. Therefore, correlations were assessed in the 196 
whole group despite known physiological differences due to pubertal development (ie, higher 197 
HOMA-IR, lower LDL-C, etc.). As expected age, male sex and pubertal stage were negatively 198 
correlated with GFR (all P < .001). Furthermore, in age- and sex-adjusted correlations, uric acid and 199 
NEFA levels were significantly correlated with GFR (r = −.24, P = .003 and r = −.20, P = .014, 200 
respectively). To evaluate if these factors were independent predictors of GFR, a stepwise 201 
multivariate linear regression was done. This analysis showed that age, sex, and uric acid levels 202 
explained a 33% of GFR variability in the studied population of children and adolescents with 203 
OW/OB (Table 2). When age was not included in the model, pubertal stage took its place in the 204 
regression model without major deviations (data not shown). As several cardiometabolic risk factors 205 
correlated with uric acid, we performed a regression analysis to evaluate the independent contributors 206 
to uric acid levels in OW/OB (Table 3). Elevated BP, age, z- BMI, and NEFA levels were independent 207 
predictors of almost half of uric acid variability in a model adjusted by pubertal stage, insulin 208 
resistance, GFR, and plasma lipids. 209 
4 | DISCUSSION 210 
The present study shows that GFR values were lower in children and adolescents with OW/OB as 211 
they present higher age, uric acid levels and go through pubertal development. On the other hand, HF 212 
in children and adolescents with T1D was related to worse metabolic and BP control, as also pointed 213 
out by others.4,5 Thus, refuting our hypothesis, the alterations of GFR were different between 214 
children and adolescents with T1D and with OW/OB without diabetes. Although contrary to a 215 
previous study,12 our results show that HF prevalence is lower in children and adolescents with 216 
OW/OB vs T1D. HF was an early event related to lower WC, NEFA, and uric acid in prepubertal 217 
children with OW/OB. The decreased presence of metabolic alterations in these patients could be 218 
explained by shorter exposure time to unhealthy weight gain. In further support to this notion, a trend 219 
toward higher prevalence of severe OB, consequence of sustained weight gain along the lifetime, was 220 
observed among prepubertal children without HF. In addition, low GFR was evident in pubertal 221 
youths with OW/OB. Our results are in line with the ones of Marzuillo et al who showed that duration 222 
of OB and puberty negatively affected GFR in OW/OB children.14 The observed differences in the 223 
GFR alterations between the studied groups could be relevant to explain the different kidney 224 
outcomes between children and adolescents with T1D vs T2D.20,21 However, whether these 225 
represent different physiopathological mechanisms or are the consequence of a more rapid 226 
development associated with longer exposure to OB or other renal disease risk factors remains 227 
unknown. In support to the latter, a recent study showed an association of GFR < 90 mL/ min.1.73 228 
m2, with male sex and elevated uric acid levels in children and adolescents (aged: 7-18 years) with 229 
T1D but without albuminuria, resembling our results in male pubertal subjects with OW/OB showing 230 
low GFR.27 Uric acid was the only biomarker that independently contributed to explain the variance 231 
of GFR in children and adolescents with OW/OB. In addition, uric acid levels summarized data from 232 
many cardiometabolic risk factors in the present series. In agreement with other studies,17,18,28 233 
elevated BP, older age, and increasing z-BMI and NEFA levels contributed to explain almost 50% of 234 
uric acid variations. In this aspect, uric acid levels as a renal disease marker in children with OW/OB 235 
merit further studies. The role of uric acid as a risk biomarker for diabetic kidney disease has already 236 
been established in children and adolescents with T2D and adults with T1D.8,19 However, in 237 
agreement with other study,10 uric acid was not correlated with renal function or cardiometabolic 238 
risk factors in our group of children and adolescents with T1D. A recent study showed that T1D 239 
duration may condition the association of uric acid with renal disease risk, limiting its use in pediatric 240 
diabetes care.29 Our study highlights several limitations to the use of HF in clinical practice in 241 
childhood OB. First, the time in which HF occurs could vary between individuals according to OB 242 
duration and pubertal development; thus, many children with higher risk of early renal impairment 243 
may go unnoticed. Second, the use of any of the proposed GFR cut-off to define HF in the clinical 244 
practice could lead to a large number of misclassified cases among children with OW/OB. If 245 
longitudinal studies confirm our results of a declining GFR during childhood OB, then percentual or 246 
absolute change values of GFR decline per time unit would be suitable for identifying youths at risk 247 
for early renal impairment. For this purpose, in the present study, the creatinine and cystatin C-248 
combined Zappitelli equation was considered adequate. While creatinine levels correlated with age 249 
and pubertal development, cystatin C concentration did not (data not shown). Thus, the use of cystatin 250 
C, having sex into consideration, would be relevant for an adequate assessment of renal function in 251 
children and adolescents with OW/OB. The correlation observed by others between GFR estimations 252 
and z-BMI could have been related to the lack of cystatin C measurement, the use of GFR equations 253 
that include weight in its formula, like the Bouvet equation, or the inclusion of normal weight 254 
individuals in the analyses.12,14,26 The present was a cross-sectional study and it was not possible 255 
to confirm if the patients with OW/OB will show or not a rapid decline in GFR. The lack of data on 256 
OB duration limited the interpretation of our results, in particular among pubertal children. In 257 
addition, non-alcoholic fatty liver disease (NAFLD), which is prevalent in childhood OB (up to 258 
34%;30), was not part of the protocol examinations. A recent report showed that NAFLD was a 259 
significant predictor of low GFR among a series of 230 children and adolescents with OW/OB (46% 260 
showing NAFLD).31 Longitudinal studies will clarify the relationship between NAFLD and impaired 261 
renal function in childhood OB. The strengths of our study rely on the exclusion of patients with 262 
microalbuminuria and with any other inflammatory condition (based on clinical and biochemical 263 
parameters) that could have affected the biochemical variables studied. In addition, the use of a 264 
creatinine and cystatin C equation for the calculation of GFR is a clear strength in comparison to 265 
other studies only using creatinine concentration. However, our classification was based only in one 266 
evaluation of the GFR and the reported frequencies of GFR alterations may be biased. Nonetheless, 267 
the observed prevalence of HF in youths with T1D and of GFR alterations in OW/OB was similar to 268 
previous reports.10,12 In the present study, the GFR reference range was previously verified in a 269 
group of 26 children and adolescents with normal weight. This point combined with the fact that 270 
subjects with HF and low GFR were found in the same study supports our evaluation of the GFR. 271 
However, the lack of metabolic data in normal weight subjects could suppose a limitation to our 272 
conclusions beyond those regarding GFR alterations. Finally, although some patients showed 2 years 273 
of diabetes duration, insulin deficiency was ascertained by a fasting C-peptide >0.2 nmol/L as an 274 
exclusion criterion. In conclusion, GFR alterations were different between children and adolescents 275 
with T1D and with OW/OB. Higher uric acid, older age, and puberty were related to lower GFR 276 
values in OW/OB children. Whether these represent different physiopathological mechanisms or are 277 
the consequence of a more rapid impairment of renal function associated with longer exposure to 278 
cardiometabolic risk factors remains to be determined. 279 
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